Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?
Di Marco V, D'Ambrosio R, Bronte F, Saracco G, Lanza AG, Forni G, Poggiali E, Calvaruso V; on behalf ITHACA (Italy for THAalassemia, hepatitis C Advances) Group. Di Marco V, et al. Among authors: lanza ag. Dig Liver Dis. 2016 Jun;48(6):650-5. doi: 10.1016/j.dld.2016.02.004. Epub 2016 Feb 21. Dig Liver Dis. 2016. PMID: 27012446
Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, Picciotto FP, Marino-Marsilia G, Fontanella L, Leandro G. Ascione A, et al. Among authors: lanza ag. Gastroenterology. 2010 Jan;138(1):116-22. doi: 10.1053/j.gastro.2009.10.005. Epub 2009 Oct 20. Gastroenterology. 2010. PMID: 19852964 Clinical Trial.
Incidence of side effects during therapy with different types of alpha interferon: a randomised controlled trial comparing recombinant alpha 2b versus leukocyte interferon in the therapy of naive patients with chronic hepatitis C.
Ascione A, De Luca M, Di Costanzo GG, Picciotto FP, Lanza AG, Canestrini C, Morisco F, Tuccillo C, Caporaso N. Ascione A, et al. Among authors: lanza ag. Curr Pharm Des. 2002;8(11):977-80. doi: 10.2174/1381612024607018. Curr Pharm Des. 2002. PMID: 11945144 Clinical Trial.
Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a.
Rijckborst V, Hansen BE, Ferenci P, Brunetto MR, Tabak F, Cakaloglu Y, Lanza AG, Messina V, Iannacone C, Massetto B, Regep L, Colombo M, Janssen HLA, Lampertico P. Rijckborst V, et al. Among authors: lanza ag. J Hepatol. 2012 May;56(5):1006-1011. doi: 10.1016/j.jhep.2011.12.007. Epub 2012 Jan 13. J Hepatol. 2012. PMID: 22245886
Effect of alcohol, cigarette smoking, and diabetes on occurrence of hepatocellular carcinoma in patients with transfusion-acquired hepatitis C virus infection who develop cirrhosis.
Di Costanzo GG, De Luca M, Tritto G, Lampasi F, Addario L, Lanza AG, Tartaglione MT, Picciotto FP, Ascione A. Di Costanzo GG, et al. Among authors: lanza ag. Eur J Gastroenterol Hepatol. 2008 Jul;20(7):674-9. doi: 10.1097/MEG.0b013e3282f762e1. Eur J Gastroenterol Hepatol. 2008. PMID: 18679071
28 results